Premium
Etoposide in combination as first‐line chemotherapy for advanced Hodgkin disease. A cancer and leukemia group B study
Author(s) -
Kirshner Jeffrey J.,
Anderson James R.,
Parker Barbara,
Barcos Maurice,
Cooper M. Robert,
Burns Linda J.,
Peterson Bruce A.,
Gottlieb Arlan J.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930301)71:5<1852::aid-cncr2820710523>3.0.co;2-t
Subject(s) - medicine , procarbazine , etoposide , vincristine , prednisone , cyclophosphamide , vinblastine , regimen , surgery , chemotherapy , oncology , gastroenterology
Background . In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Methods . Thirty‐six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophosphamide (MOPLEC), and then treated with five to seven additional courses of a known “curative” regimen: nitrogen mustard, vinblastine, prednisone, and procarbazine (MVPP). Results . After treatment with MOPLEC, there were 16 complete responders (44%) and 18 partial responders (50%). One patient had progressive disease and one patient was taken off study after an anaphylactic reaction to etoposide. After completing the entire protocol, 32 patients achieved complete remission (CR) (89%) and 3 achieved partial remission (PR) (8%). Five CR patients have relapsed and three additional patients have died in CR without recurrence. At 36 months, the estimated failure‐free survival is 61% and overall survival is 72%. Conclusions . This combination, which includes etoposide, is active for the primary treatment of advanced Hodgkin disease.